ClinicalTrials.Veeva

Menu

A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.

Medical University of Vienna logo

Medical University of Vienna

Status

Enrolling

Conditions

ATTR Amyloidosis With Cardiomyopathy
Mitral Regurgitation
ATTR Amyloidosis Wild Type
ATTR-CM
Tricuspid Regurgitation

Study type

Observational

Funder types

Other

Identifiers

NCT06836011
ATTR-CM-AVR-2025-001

Details and patient eligibility

About

The objective of this prospective registry study is to comprehensively characterize the prevalence, (semi-) quantitative parameters, and associated clinical outcomes of mitral (MR) and tricuspid regurgitation (TR) in patients diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM). The study further aims to develop and implement new grading standards for the quantitative assessment of regurgitation severity, tailored to the distinct hemodynamic profile of ATTR-CM. This approach seeks to address the limitations of current regurgitation severity classifications, which do not adequately reflect the unique pathophysiology of a restrictive phenotype as seen in ATTR-CM.

Enrollment

600 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of ATTR-CM according to current diagnostic criteria
  • Comprehensive baseline echocardiographic assessment, including (semi-)quantitative mitral and tricuspid regurgitation (MR/TR) parameters, performed within ±6 months of diagnosis
  • Age ≥ 18 years
  • Willingness to participate in the study and provide informed consent

Exclusion criteria

  • Severe aortic valve disease requiring intervention
  • Inability to provide informed consent or participate in study follow-up

Trial contacts and locations

8

Loading...

Central trial contact

Christian Nitsche, Priv.-Doz. Dr., PhD; Laurenz Hauptmann, Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems